The intestinotrophic effects of glucagon-like peptide-2 (GLP-2) in relation to intestinal neoplasia

The intestinotrophic effects of glucagon-like peptide-2 (GLP-2) in relation to intestinal neoplasia Abstract Context Glucagon-like peptide-2 (GLP-2) is a gastrointestinal hormone with intestinotrophic and anti-apoptotic effects. The hormone’s therapeutic potential in intestinal diseases and relation to intestinal neoplasia have raised great interest among researchers. This paper reviews and discusses published experimental and clinical studies concerning the growth-stimulating and anti-apoptotic effects of GLP-2 in relation to intestinal neoplasia. Evidence acquisition The data used in this narrative review were collected through literature research in PubMed using English keywords. All studies to date examining GLP-2’s relation to intestinal neoplasms have been reviewed in this article, as the studies on the matter are sparse. Evidence synthesis GLP-2 has been found to stimulate intestinal growth through secondary mediators and through the involvement of Akt phosphorylation. Studies on rodents have shown that exogenously administered GLP-2 increases the growth and incidence of adenomas in the colon, suggesting that GLP-2 may play a significant role in the progression of intestinal tumours. Clinical studies have found that exogenous GLP-2 treatment is well-tolerated for up to 30 months, but the tolerability for even longer periods of treatment has not been examined. Conclusion Exogenous GLP-2 is currently available as teduglutide for the treatment of short bowel syndrome. However, the association between exogenous GLP-2 treatment and intestinal neoplasia in humans has not been fully identified. This leads to a cause for concern regarding the later risk of the development or progression of intestinal tumours with long-term GLP-2 treatment. Therefore, further research regarding GLP-2’s potential relation to intestinal cancers is needed. Copyright © 2018 Endocrine Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

The intestinotrophic effects of glucagon-like peptide-2 (GLP-2) in relation to intestinal neoplasia

Loading next page...
 
/lp/ou_press/the-intestinotrophic-effects-of-glucagon-like-peptide-2-glp-2-in-4hgQnKB0zZ
Publisher
Endocrine Society
Copyright
Copyright © 2018 Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
D.O.I.
10.1210/jc.2018-00655
Publisher site
See Article on Publisher Site

Abstract

Abstract Context Glucagon-like peptide-2 (GLP-2) is a gastrointestinal hormone with intestinotrophic and anti-apoptotic effects. The hormone’s therapeutic potential in intestinal diseases and relation to intestinal neoplasia have raised great interest among researchers. This paper reviews and discusses published experimental and clinical studies concerning the growth-stimulating and anti-apoptotic effects of GLP-2 in relation to intestinal neoplasia. Evidence acquisition The data used in this narrative review were collected through literature research in PubMed using English keywords. All studies to date examining GLP-2’s relation to intestinal neoplasms have been reviewed in this article, as the studies on the matter are sparse. Evidence synthesis GLP-2 has been found to stimulate intestinal growth through secondary mediators and through the involvement of Akt phosphorylation. Studies on rodents have shown that exogenously administered GLP-2 increases the growth and incidence of adenomas in the colon, suggesting that GLP-2 may play a significant role in the progression of intestinal tumours. Clinical studies have found that exogenous GLP-2 treatment is well-tolerated for up to 30 months, but the tolerability for even longer periods of treatment has not been examined. Conclusion Exogenous GLP-2 is currently available as teduglutide for the treatment of short bowel syndrome. However, the association between exogenous GLP-2 treatment and intestinal neoplasia in humans has not been fully identified. This leads to a cause for concern regarding the later risk of the development or progression of intestinal tumours with long-term GLP-2 treatment. Therefore, further research regarding GLP-2’s potential relation to intestinal cancers is needed. Copyright © 2018 Endocrine Society

Journal

Journal of Clinical Endocrinology and MetabolismOxford University Press

Published: May 7, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off